Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments, Significant Contracts and Contingencies (Tables)

Commitments, Significant Contracts and Contingencies (Tables)

12 Months Ended

Aug. 31, 2023

Commitments, Significant Contracts and Contingencies

Schedule of operating lease liabilities

		August 31, 2023				August 31, 2022
Right of use assets - operating leases		$	52,444			$	91,041
Amortization			(41,564	)			(38,597	)
Extension-related remeasurement			156,566
Total lease assets		$	167,446			$	52,444

Liabilities:		$	49,988			$	89,393
Lease payments			(44,814	)			(44,600	)
Interest accretion			2,227				5,195
Extension-related remeasurement			156,566
Total lease liabilities		$	163,967			$	49,988

Operating lease cost		$	167,446			$	52,444
Operating cash flows for lease		$	44,814			$	44,599
Remaining lease term		5.17 Years				1.17 Years
Discount rate			7.25	%			7.25	%

Schedule of maturities of operating lease liabilities

2024			35,840
2025			37,094
2026			37,345
2027			38,642
2028			38,901
2029			6,483
Thereafter			-
Total lease payments			194,305
Less: imputed interest			(30,338	)
Present value of operating lease liabilities			163,967
Less: current obligations under leases			(27,794	)
Non-Current Portion			136,173